A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 2,981 shares of BEAM stock, worth $80,665. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,981
Previous 2,457 21.33%
Holding current value
$80,665
Previous $57,000 28.07%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$22.57 - $33.14 $11,826 - $17,365
524 Added 21.33%
2,981 $73,000
Q2 2024

Jul 30, 2024

SELL
$21.22 - $32.66 $4.7 Million - $7.23 Million
-221,472 Reduced 98.9%
2,457 $57,000
Q1 2024

May 01, 2024

BUY
$23.46 - $45.07 $1.35 Million - $2.59 Million
57,554 Added 34.59%
223,929 $7.4 Million
Q4 2023

Jan 24, 2024

SELL
$17.69 - $30.76 $2.82 Million - $4.9 Million
-159,307 Reduced 48.91%
166,375 $4.53 Million
Q3 2023

Oct 26, 2023

BUY
$23.01 - $32.46 $711,216 - $1 Million
30,909 Added 10.49%
325,682 $7.83 Million
Q2 2023

Aug 10, 2023

BUY
$29.32 - $35.99 $1.99 Million - $2.44 Million
67,819 Added 29.88%
294,773 $9.41 Million
Q1 2023

May 04, 2023

BUY
$30.15 - $48.79 $315,640 - $510,782
10,469 Added 4.84%
226,954 $6.95 Million
Q4 2022

Feb 09, 2023

SELL
$36.73 - $51.6 $1.1 Million - $1.54 Million
-29,879 Reduced 12.13%
216,485 $8.47 Million
Q3 2022

Nov 10, 2022

BUY
$39.79 - $70.31 $1.33 Million - $2.35 Million
33,357 Added 15.66%
246,364 $11.7 Million
Q2 2022

Jul 26, 2022

BUY
$29.86 - $62.36 $6.36 Million - $13.3 Million
213,007 New
213,007 $8.25 Million

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.9B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Mirae Asset Global Investments Co., Ltd. Portfolio

Follow Mirae Asset Global Investments Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.